Ardelyx

Update in progress

ARDX (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Ardelyx, Inc. discovers, develops, and markets medicines to treat unmet medical needs in the United States and internationally. Its portfolio includes IBSRELA, a minimally absorbed oral therapy for irritable bowel syndrome with constipation, and XPHOZAH, a phosphate absorption inhibitor to lower serum phosphorus in adults with chronic kidney disease on dialysis. Formerly Nteryx, Inc., the company changed its name to Ardelyx in June 2008 after being incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Company score

Sentiment: 0.02; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: -0.01; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.25; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.06; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.02; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive